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doi:10.1016/j.jfma.2009.09.001Crohn disease is a chronic inflammatory disorder, which is rare in pediatric patients. The defi-
nite etiology and mechanism to induce an acute exacerbation of Crohn disease remains mostly
unknown. The authors report on a 14-year-old girl with Crohn disease who has acute gastroin-
testinal symptoms caused by toxin A-producing Clostridium difficile, which mimicked a flare-
up of Crohn disease. There was no preceding antibiotic prescription before the episode. The
disease activity did not improve after steroid treatment, which is unusual for Crohn disease.
However, all symptoms were dramatically relieved after eradication of C difficile, and led
to a symptom-free period for more than 3 years. This case report aims to address the unusual
presentation of a usual pathogen, C difficile, in a pediatric patient with Crohn disease.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Crohn disease is a chronic inflammatory disorder with no
clearly elucidated etiology and pathogenesis. Current
theories indicate that genetic, microbial, immunologic,
environmental, and dietary factors are all involved as
potential causes. Most of the genes related to the devel-
opment of Crohn disease are involved in mucosal immunitynt of Pediatrics, National
han South Road, Taipei 100,
Y.-H. Ni).
ight ª 2012, Elsevier Taiwan LLCand the mucosal barrier epithelium.1 Most patients might
have an aberrant immunologic response to one or more of
these provoking factors, resulting in the flare-up of Crohn
disease. Infectious pathogens such as Mycobacterium par-
atuberculosis, Pseudomonas species, and Listeria species
have all been implicated as provoking factors in the path-
ogenesis of Crohn disease.1
Case report
A14-year-old girlwas admitted to thehospital because of a 2-
day history of fresh bloody stool. The diagnosis of Crohn
disease hadbeenmade 14months prior to this admission.Her
initial symptoms were recurrent abdominal pain, bloody& Formosan Medical Association. All rights reserved.
348 C.-H. Hsu et al.diarrhea, and low-grade fever. Colonoscopy revealed a deep
ulcer, and a circumferential cobblestone appearance was
noted (Fig. 1A). The pathologic examination then showed
dense acute and chronic inflammatory cell infiltration in the
lamina propria and submucosa, and frequent crypt abscesses
(Fig. 1B and 1C). She was treated with prednisolone and
mesalamine, and prednisolone therapy was discontinued 5
months after the onset of symptoms. She experienced one
relapse, which was successfully treated with a 1-month
regimen of prednisolone (2 mg/kg/day).
The abdominal pain and blood-tinged stool recurred 2
weeks after prednisolone was discontinued. She lost 3 kg in
1 week before admission. Colonoscopy was performed and
revealed multiple ulcers and inflammatory polyps (Fig. 2A).
Pathology showed focal ulceration of colonic mucosa with
leukocyte aggregation in the lamina propria (Fig. 2B).
Esophagogastroduodenoscopy was performed, with nega-
tive findings. The laboratory data on admission were as
follows: normal complete blood count, albumin 4.3 mg/dL,
erythrocyte sedimentation rate (ESR) 41 and 70 mm/hour in
the first and second hour, respectively. The stool guaiac
test was strongly positive with many pus cells. The pedi-
atric Crohn disease activity index (PCDAI) was 35 points.2
Anemia developed 1 week later. Metronidazole was
prescribed 2 days before admission and was changed to
ciprofloxacin because the patient could not tolerate
metronidazole. Prednisolone (2 mg/kg/day) and mesal-
amine were prescribed again. Azathioprine (1.25 mg to 2.5/
kg/day) was added later, and was changed to mercapto-
purine (1.25 mg/kg/day) after 1 week.
The patient’s stool culture collected on admission showed
Clostridium difficile. We confirmed the positive data of C
difficile toxin A twice by enzyme immunoassay (VEDA lab
Toxin A-check-1 test, Analytica, Ltd. Moscow, Russia). The
patient started to take oral vancomycin (18.75 mg/kg/day)
after being treated with steroid plus immunosuppressant
therapy for 14 days. She regained her appetite a few days
later, and the symptomssubsideddramaticallywithin1week.
PCDAI was zero before discharge. The patient remained
symptom free and ESR was normal for more than 3 years.Figure 1 (A) Colonoscopy after the first episode of Crohn diseas
appearance between 50 cm and 55 cm from the anal verge. (B)
submucosa (hematoxylin and eosin stain, 200). (C) Frequent crypDiscussion
Crohn disease is an idiopathic, chronic inflammatory disorder
of the bowel, involving any region along the gastrointestinal
tract. The diagnosis is made when the clinical history and
radiographic, endoscopic, and histologic findings are
compatible. Clinically, the symptoms and pathologic finding
of C difficile infection mimic active Crohn disease. In our
patient, it was very difficult to differentiate the pathologic
finding from those two disease entities. C difficile is a spore-
forming gram-positive bacillus that produces two toxins:
toxinA (enterotoxin) acts on the intestinalmucosa toproduce
diarrhea; toxin B (cytotoxin) increases vascular permeability
in low doses and is lethal in high doses in experimental
animals. The anaerobic stool culture may have high sensi-
tivity, but when used alone without toxin testing, it leads to
low specificity and misdiagnosis of C difficile-associated
diseases when high rates of asymptomatic carriage exist.
Therefore, the diagnosis of C difficile-associated diseases is
established by culture and toxin detection, a so-called toxi-
genic culture.3 Previous antibiotic use is the predominant risk
factor for C difficile acquisition. Intravenous vancomycin,
fluoroquinolones, and first-, third-, or fourth-generation
cephalosporins are associated with a relatively high risk.
The stool culture of this patientwas assessed after only 2 days
of treatment with metronidazole. Such a short duration
of metronidazole use actually ran a low risk to develop
C difficile-associated disease.4 Thus, we suggested that this
patient’s symptoms are related to Crohn disease rather than
an antibiotic-related disease.
Increasing evidence supports the theory that an unbal-
anced host immune response induced by enteric pathogens
may result in Crohn disease.5 Intestinal permeability changes
in relatives of patients with Crohn disease have been docu-
mented, which may facilitate the penetration of antigens
and trigger the aberrant immune response.6 To date, no
specific pathogen has been proved to be a potential factor of
inflammatory bowel disease (IBD), although the relationship
of bacterial involvement cannot be excluded. C difficile is
known as the most common pathogen in enteric infection ofe demonstrated deep ulcers and circumferential cobble stone
The inflammatory cell infiltration in the lamina propria and
t abscesses (hematoxylin and eosin stain, 200).
Figure 2 (A) Colonoscopy performed during relapsed symptoms revealed multiple ulcers and tiny polyps at 85 cm above the anal
verge. (B) Leukocytes aggregated in the lamina propria (hematoxylin and eosin stain, 400).
Clostridium difficile infection in a patient with Crohn disease 349IBD. The association of theCdifficile toxinwith symptomatic
relapse in severe IBD was reported in 1980. Afterward, the
noted incidence of C difficile increased significantly in
patients with IBD, and such an infection may worsen the
clinical outcome.7 Functional toll-like receptors (TLR) and
associated pathways are known to play a key role in the
initiation andperpetuation of these inflammatory responses.
On the genetic background of Crohn disease, the well-known
mutation is the nucleotide oligomerization domain 2/cas-
pase activating recruitment domain 15 (NOD2/CARD15) gene
located at 16q12 that that contributes to persistent bowel
inflammation by causing excessive TLR2 cytokine responses.8
However, this mutation is not associated with Crohn disease
in Taiwanese children.9 The reason that patients with Crohn
disease respond differently than healthy individuals remains
unclear. We speculate that there are some interactions
between C difficile and host innate immunity that result in
chronic inflammation.
In adult patients, it has been reported that patients with
IBD and concomitant C difficile infection experience
increased morbidity and mortality.10 Because C difficile
colitis will both mimic and precipitate an IBD flare-up, early
detection and treatment against the pathogen is important
and difficult. In pediatric patients with Crohn disease, the
role of C difficile remains mostly unknown. However, as in
this patient, the disease activity was not suppressed until
the initiation of the anti-C difficile therapy. Such a case
report may indicate that C difficile without timely treat-
ment might cause an intractable flare-up of Crohn disease.
The regimen for C difficile-associated diarrhea includes
oral vancomycin, metronidazole, teicoplanin, fusidic acid,
and rifaximine. In adults, teicoplanin may be more effec-
tive than vancomycin for a bacteriologic and symptomatic
cure, and metronidazole is just as effective.11 Most patients
are treated with steroid and immunosuppressive medica-
tion at the time they acquired C. difficileinfection. A rapid
decrease in steroid dosing after detection of the infection
may correlate with a lower rate of surgery.12 A more
aggressive approach for the treatment of C difficile infec-
tion was advocated recently, but the treatment of Crohn
disease should never be delayed.7Remission in our patient was accomplished by successful
treatment with C difficile. The relationship of C difficile
and the enteric immune system in Taiwanese children may
need further investigation. This case also highlights that C
difficile may be key for further research of the patho-
physiology of Crohn disease.References
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